Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib with or without Tislelizumab in Metastatic Melanoma
NCT05104801Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sitravatinib in melanoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Overall Response Rate at 12 months. Status: unknown.
02
Drugs
sitravatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05104801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104801.